{
  "asset": {
    "name": "CDK2 degraders",
    "company": "Kymera Therapeutics",
    "ticker": "KYMR",
    "target": "CDK2",
    "mechanism": "Molecular glue degrader",
    "modality": "Oral molecular glue degrader",
    "partner": "Gilead"
  },
  "clinical_development": {
    "current_stage": "Preclinical",
    "indications_in_development": [
      "Breast cancer",
      "Other solid tumors"
    ]
  },
  "trials": [],
  "investment_thesis": [],
  "key_risks": [],
  "upcoming_catalysts": [],
  "_source_pages": [
    11,
    52,
    65
  ],
  "_last_extracted": "2026-02-04T13:13:42.036406"
}